Texas Permanent School Fund lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) by 2.6% during the second quarter, Holdings Channel reports. The institutional investor owned 58,070 shares of the company’s stock after purchasing an additional 1,457 shares during the quarter. Texas Permanent School Fund’s holdings in Myriad Genetics were worth $1,055,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. First Horizon Advisors Inc. purchased a new stake in shares of Myriad Genetics in the second quarter valued at approximately $57,000. Exchange Traded Concepts LLC boosted its stake in shares of Myriad Genetics by 216.7% in the second quarter. Exchange Traded Concepts LLC now owns 3,588 shares of the company’s stock valued at $65,000 after buying an additional 2,455 shares in the last quarter. US Bancorp DE boosted its stake in shares of Myriad Genetics by 14.6% in the first quarter. US Bancorp DE now owns 4,243 shares of the company’s stock valued at $108,000 after buying an additional 541 shares in the last quarter. KBC Group NV purchased a new stake in shares of Myriad Genetics in the second quarter valued at approximately $127,000. Finally, Captrust Financial Advisors boosted its stake in shares of Myriad Genetics by 103.2% in the first quarter. Captrust Financial Advisors now owns 5,083 shares of the company’s stock valued at $128,000 after buying an additional 2,581 shares in the last quarter. 99.80% of the stock is currently owned by hedge funds and other institutional investors.
Myriad Genetics Trading Down 1.3 %
Shares of Myriad Genetics stock opened at $19.02 on Friday. Myriad Genetics, Inc. has a twelve month low of $15.38 and a twelve month high of $28.60. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -19.61 and a beta of 1.71. The business’s 50 day simple moving average is $19.55 and its 200-day simple moving average is $21.01.
Analyst Upgrades and Downgrades
Myriad Genetics Company Profile
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.